These findings strongly suggested that TACC3 was down-regulated after treatment with HDACIs and up-regulated in CCA tissues compared with adjacent non-tumor tissues, and that TACC3 may be a potential anti-tumor molecular drug target of HDACIs in CCA. Here, TACC3 is linked to cholangiocarcinoma.